Activating Compound | Comment | Organism | Structure |
---|---|---|---|
additional information | NO treatment elevates the enzyme activity shortly after application, but does not significantly affect the steady-state levels of cGMP | Sus scrofa |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one | acute addition to pulmonary artery does not affect phenylephrine responsiveness, but restores the responsiveness in pulmonary artery treated with an NO-donor, overview | Sus scrofa |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
soluble | - |
Sus scrofa | - |
- |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
GTP | Sus scrofa | - |
3',5'-cyclic GMP + diphosphate | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
artery | pulmonary, cultured model | Sus scrofa | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
0.29 | - |
pulmonary artery homogenate in absence of NO | Sus scrofa |
0.53 | - |
pulmonary artery homogenate after 24 h of treatment with NO | Sus scrofa |
1.38 | - |
pulmonary artery homogenate after 2 h of treatment with NO | Sus scrofa |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
GTP | - |
Sus scrofa | 3',5'-cyclic GMP + diphosphate | - |
? |
Synonyms | Comment | Organism |
---|---|---|
sGC | - |
Sus scrofa |
soluble guanylyl cyclase | - |
Sus scrofa |